Literature DB >> 24852043

High prevalence of cross-resistance to aminoglycosides in fluoroquinolone-resistant Escherichia coli clinical isolates.

Naoyuki Tsukamoto1, Yasuo Ohkoshi, Torahiko Okubo, Toyotaka Sato, Osamu Kuwahara, Nobuhiro Fujii, Yutaka Tamura, Shin-Ichi Yokota.   

Abstract

BACKGROUND: Multidrug-resistant Escherichia coli, especially a lineage of O25b:H4-ST131, has increased and spread worldwide. The surveillance of cross-resistance of E. coli is necessary.
METHODS: Cross-resistance to fluoroquinolones (FQs) and aminoglycosides (AGs) was examined in E. coli isolated in Hokkaido Prefecture, Japan, between 2008 and 2009.
RESULTS: Gentamicin (GEN) resistance was more common in FQ-resistant isolates (30/112 strains; 26.8%) than in FQ-susceptible isolates (2/100 strains; 2%). The frequency of GEN resistance was similar in two groups of FQ-resistant strains, O25b:H4-ST131 genotype (22/87 strains; 25.3%) and a group of other FQ-resistant genotypes (8/25 strains; 32.0%). The main AG resistance gene was aac(3)-II (87.5% of GEN-resistant strains). The only amikacin-resistant strain which was FQ resistant carried the aac(6')-Ib-cr gene. CTX-M type extended-spectrum β-lactamase (ESBL) genes were also found in FQ-resistant strains at a high frequency. However, the number of strains with both ESBL and AG-modifying enzyme genes was relatively low (8 strains).
CONCLUSION: All FQ-resistant strains, not only O25b:H4-ST131, appeared to preferentially acquire ESBL genes and/or genes encoding AG-modifying enzymes; however, the acquisitions of these genes seemed to occur independently.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24852043     DOI: 10.1159/000361011

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  6 in total

1.  Tigecycline Nonsusceptibility Occurs Exclusively in Fluoroquinolone-Resistant Escherichia coli Clinical Isolates, Including the Major Multidrug-Resistant Lineages O25b:H4-ST131-H30R and O1-ST648.

Authors:  Toyotaka Sato; Yuuki Suzuki; Tsukasa Shiraishi; Hiroyuki Honda; Masaaki Shinagawa; Soh Yamamoto; Noriko Ogasawara; Hiroki Takahashi; Satoshi Takahashi; Yutaka Tamura; Shin-Ichi Yokota
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

2.  Antibiotic Multidrug Resistance of Escherichia coli Causing Device- and Procedure-related Infections in the United States Reported to the National Healthcare Safety Network, 2013-2017.

Authors:  Athena P Kourtis; Edward A Sheriff; Lindsey M Weiner-Lastinger; Kim Elmore; Leigh Ellyn Preston; Margaret Dudeck; L Clifford McDonald
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 20.999

3.  Mechanism of Reduced Susceptibility to Fosfomycin in Escherichia coli Clinical Isolates.

Authors:  Yasuo Ohkoshi; Toyotaka Sato; Yuuki Suzuki; Soh Yamamoto; Tsukasa Shiraishi; Noriko Ogasawara; Shin-Ichi Yokota
Journal:  Biomed Res Int       Date:  2017-01-19       Impact factor: 3.411

4.  Comprehensive Molecular Characterization of Escherichia coli Isolates from Urine Samples of Hospitalized Patients in Rio de Janeiro, Brazil.

Authors:  Ana Carolina C Campos; Nathália L Andrade; Mithila Ferdous; Monika A Chlebowicz; Carla C Santos; Julio C D Correal; Jerome R Lo Ten Foe; Ana Cláudia P Rosa; Paulo V Damasco; Alex W Friedrich; John W A Rossen
Journal:  Front Microbiol       Date:  2018-02-16       Impact factor: 5.640

5.  Effects of Selected Egyptian Honeys on the Cellular Ultrastructure and the Gene Expression Profile of Escherichia coli.

Authors:  Reham Wasfi; Walid F Elkhatib; Ahmed S Khairalla
Journal:  PLoS One       Date:  2016-03-08       Impact factor: 3.240

6.  Multidrug-Resistant Escherichia coli and Klebsiella pneumoniae Isolated From Patients in Kashan, Iran.

Authors:  Atieh Sadat Moini; Babak Soltani; Abbas Taghavi Ardakani; Alireza Moravveji; Mahzad Erami; Mostafa Haji Rezaei; Mansoor Namazi
Journal:  Jundishapur J Microbiol       Date:  2015-10-25       Impact factor: 0.747

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.